Background: The incidence of symptomatic brain metastases in small-cell carcinoma of the urinary bladder (SCBC) is unknown. This precludes advice about prophylactic cranial irradiation (PCI).
introduction Small-cell carcinoma of the urinary bladder (SCBC) is one of the most common sites of extrapulmonary small-cell carcinoma, although it accounts for only 1% of all bladder tumors [1] . The first case of primary small-cell bladder cancer was reported in 1981 [2] . Since then, some 600 cases diagnosed according to the World Health Organization (WHO) criteria [3] have been published in small series and case reports.
The low incidence of SCBC precludes prospective randomized trials and the optimal therapeutic strategy remains uncertain. Analogous to small-cell lung cancer (SCLC), a clinically relevant two-stage system of limited disease (LD) and extensive disease (ED) is widely adopted to determine prognosis and treatment. About one-third (14%-44%) of the patients with SCBC present with LD [4, 5] . Although cases in which locally confined disease was curable by resection alone have been reported, local therapy often fails due to the presence of micrometastases at diagnosis [6] . Again, similar to the treatment of SCLC, neoadjuvant or adjuvant platinum-based chemotherapy is therefore advised and has been associated with significantly improved survival [7] [8] [9] . Cystectomy with systemic chemotherapy has been propagated as well as combinations of chemotherapy with transurethral resection (TUR), partial cystectomy, and radiotherapy [6, 7, [9] [10] [11] .
SCLC patients who achieve a remission after initial treatment with chemotherapy with or without chest radiation are considered for prophylactic cranial irradiation (PCI). Patients in whom the cancer can be controlled outside the brain have a 60% risk of developing brain metastases within 2-3 years after primary treatment [12, 13] . The risk of developing brain metastases can be reduced by 26%-50% with the administration of PCI, also leading to improved disease-free and overall survival [13] [14] [15] [16] . Prospective studies showed that patients treated with PCI using modern techniques do not have a persistent decline in cognitive functions as compared with patients that were not irradiated [17] . Nevertheless, long-term toxicity, especially delayed neurocognitive impairment, remains a potential concern. Following the recommendation for PCI in SCLC, its use is sometimes also advocated in patients with SCBC [4, 18, 19] . However, the efficacy of PCI in SCBC is uncertain because of a lack of information on the incidence of symptomatic brain metastases in SCBC. We evaluated the original article (CaE) (days 1-3), repeated after 21 days. Radiotherapy was applied using 8-18 MV photons with a three-or fourfield technique. The mean dose was 60 Gy varying from 56 to 70. The target area consisted of the bladder and the tumor. In case the total dose was 70 Gy, 50 Gy was given to bladder and tumor with a 20-Gy boost to the bladder tumor area only.
Follow-up visits after a curative treatment approach were scheduled every 3 months. Local response in the bladder was assessed by cystoscopy, cytology, and CT scan. In case of suspicious findings at cystoscopy, a TUR was carried out for pathological assessment of disease progression. RECIST criteria were used to assess systemic disease progression. Imaging of the brain (CT scan or magnetic resonance imaging) was carried out only in case of neurological symptoms indicative of brain metastases. No patient received PCI.
statistical methods
Disease-specific survival was defined as the time from diagnosis to death due to SCBC or to last follow-up date. Patients dying of causes other than SCBC were censored. Survival within each disease stage subgroup was estimated using the Kaplan-Meier method.
literature search
For the literature review, we searched the electronic databases Medline, EMBASE, and CancerLit using the key words bladder, small cell, and neuroendocrine. Hand searching of journals, relevant books, and review articles was also carried out. Only series with five or more patients were included in the analysis. results A total of 51 consecutive patients with SCBC were identified during the study period. The histological diagnosis was on the basis of biopsy material in 43 patients and the surgical specimen in 8. None of the patients had evidence of a primary tumor in the lung. Patient characteristics are summarized in Table 1 . The median age was 65 years, with a male predominance of 80%.
Thirty-nine patients had LD and 12 patients had ED. The median survival of all patients with SCBC was 28 months. Patients with LD had a median survival of 35 months compared (Figure 1) . The 1-and 5-year survival rates in patients with LD were 83% and 43%, respectively. We discussed the bladder-sparing treatment strategy of chemoradiation following TUR leading to long-term survival of patients with LD in a previous publication [20] . One patient with ED is in complete remission 43 months after chemotherapy for biopsy-proven liver metastases. If we group the results according to TNM stage, patients with less than or equal to cT 2 N 0 M 0 disease had a median survival of 35 months, compared with 15 months for higher stage tumors (higher than or equal to T 3b , N + , or M + ).
None
Twelve patients with ED were offered palliative chemotherapy only. Twenty-one patients with LD were offered a bladdersparing approach with external beam radiotherapy and concomitant and/or sequential platinum-based chemotherapy, with curative intent [20] . In eight patients, the diagnosis of SCBC was made after cystectomy in addition to the earlier diagnosis of urothelial carcinoma at TUR. Despite having LD, these patients did not receive adjuvant chemotherapy as this was no policy at our institution at that time. Two patients with known LD underwent cystectomy because either radiotherapy (prior prostate cancer radiotherapy) or chemoradiotherapy (large bleeding tumor with renal dysfunction) could not be applied. Eight patients with LD did not receive chemotherapy due to age-associated comorbidity or due to unknown histology at treatment and were treated with TUR of the bladder and subsequent radiotherapy only.
discussion
The management of SCBC is tailored after SCLC. Patients are stratified according to disease extension (LD or ED) and treatment involves platinum-based chemotherapy either alone if the intent is palliative or in combination with radiotherapy or sometimes surgery if diagnosis is made early and cure is still feasible.
Sufficient data have demonstrated the similarity in the clinical course between SCBC and SCLC, although the median survival for patients with SCLC is generally shorter than that for patients described in our series [21] . A large literature review of SCBC identified ED, not tumor size, as a predictor of poor outcome and only cisplatin-based chemotherapy, not primary surgery, improved survival [7] . This observation indicates that micrometastases are often present in clinically localized disease. Because of these clinicopathological similarities between SCLC and SCBC and their clinical relevance, we and others define LD and ED SCBC in analogy to SCLC.
Brain metastases are common in SCLC, with increasing incidence over time. Patients with controlled SCLC outside the brain have up to a 60% risk of developing brain metastases within 2-3 years after starting treatment. Previously, PCI was offered to all patients who had a complete response to chemotherapy. This strategy resulted in a median survival of 18-24 months [22] [23] [24] . Recently, a large European trial conducted by the European Organisation for Research and Treatment of Cancer Radiation Oncology and Lung Cancer Groups has demonstrated a benefit for disease-free and overall survival following PCI in patients who have any response to chemotherapy, regardless of the extent of the disease [15] . PCI decreased the cumulative incidence of symptomatic brain metastases at 1 year by 26% with only mild adverse effects [14, 25] . Following these arguments and the otherwise similarity with SCLC, PCI is often considered in SCBC as well, albeit lacking evidence for its efficacy.
Twenty-one retrospective series have addressed the clinical course of SCBC. Fifteen publications report details on the occurrence of brain metastases with an estimated risk of 0%-40% (Table 2) [4, 9-11, 18, 19, 21, 26-33] . Most publications, however, do not clearly differentiate between prevalent and incident cases of brain metastases nor do they describe the time to progression or an association with histopathological subtypes (pure small-cell or mixed histology).
Siefker-Radtke et al. [19] reported on a phase II trial of alternating doublet chemotherapy with ifosfamide plus doxorubicin and etoposide plus cisplatin that showed a 27% incidence of brain metastases among 30 patients. The authors found that the incidence of brain metastases was associated with disease extension. Brain metastases occurred in 8 (50%) of 16 patients with bulky higher stage tumors (higher than or equal to T 3b , N + , or M + ) but not in the 14 patients with less than or equal to cT 2 N 0 M 0 disease. Once brain metastases developed, nearly all patients died within 2 months after this diagnosis. On the basis of the subgroup analysis of 16 patients, the authors indicate that PCI may be considered in patients with higher stage tumors.
Pooling all patients (n = 291) from the 15 published series in which metastatic sites were mentioned, we identified 33 original article Annals of Oncology patients who either had brain metastases at diagnosis or developed brain metastases during follow-up (11.3%). Combining them with our series, 37 brain metastases in 342 patients yield a cumulative incidence of 10.8% (95% confidence interval 7.5% to 14.1%) (Figure 2 ). This estimate should be interpreted with some caution, however, as prevalent and incident cases are combined and differences in disease stage, treatment, and follow-up exist. In addition, the diagnosis of brain metastases was sometimes made on the basis of screening imaging of the brain in the absence of neurological symptoms. Only three centers reported PCI in some of their patients with LD [4, 18, 19] .
An important reason for offering PCI to patients with SCLC is the high rate of brain metastases of 60%, which is four-to eightfold higher than the pooled estimate for SCBC. The high rate of brain metastases in SCLC is attributed to the fact that most chemotherapeutic agents do not adequately penetrate the blood-brain barrier. The discrepancy in the occurrence of brain 
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metastases between SCLC and SCBC is not well understood. Except for small-cell cancer of the head and neck region, extrapulmonary small-cell cancer shows invariably low incidence of brain metastases [34] . Given the striking similarity in the cellular and molecular makeup of SCLC and extrapulmonary small-cell cancers, other causes must be responsible for the difference in incidence of brain metastases. Variation in hematologic and lymphatic draining patterns of the respective topographical-anatomical places of origin (lung versus bladder) is likely to play a role. The incidence of brain metastases in SCBC, however, is three-to ninefold higher than that in transitional cell carcinoma of the bladder (TCCB) [35] [36] [37] .
Evidence from the literature supports that the small-cell component is the leading prognosticator in bladder tumors with mixed histology [6, 7, 9, 10] . Such tumors should therefore be managed like pure SCBC. The TCCB, adenocarcinoma, or squamous cell components have no apparent prognostic influence [11, 21, 33] . Three of our early patients were treated with MVAC if the TCCB component obtained at TUR was significantly present (>50%), possibly influencing our results. Neither in our series nor in the literature, however, did we find an association of histology with the occurrence of brain metastases.
We included all patients with SCBC who were treated in our Institution since 1993. Bias may have occurred, however, due to selective referral from other hospitals. Referral is more likely for lower-stage tumors and for patients with less comorbidity. This may explain the relative favorable outcome of our study population compared with the literature. Nevertheless, some of our patients did not receive optimal (platinum-based) chemotherapy because of their performance status or comorbidity. We decided to include these patients in our study as it best reflects clinical practice. None of the patients with ED in our series developed symptomatic brain metastases. This may point to an association between survival time and risk of developing symptomatic brain metastases. Rapid disease progression elsewhere and death may have precluded the onset of symptomatic brain metastases. This may imply that if treatment strategies become available that improve the survival of patients with SCBC, the incidence of brain metastases may also rise.
This retrospective analysis and review of the literature reveals that the incidence of symptomatic brain metastases from SCBC is increased when compared with TCCB but is importantly lower than in SCLC. On the basis of the available evidence, there are no data to support that PCI is superior to cranial irradiation in symptomatic SCBC patients. As a result, we do not routinely advise PCI in patients with SCBC.
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